Zevra Therapeutics Inc. (ZVRA) — Cash Flow-to-Debt Ratio
Zevra Therapeutics Inc. (ZVRA) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of $4.71 Million could theoretically repay 0% of its total liabilities ($136.95 Million) in one year. See Zevra Therapeutics Inc. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Zevra Therapeutics Inc. Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Zevra Therapeutics Inc. across 13 annual periods. For the full cash flow conversion analysis, see Zevra Therapeutics Inc. (ZVRA) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Zevra Therapeutics Inc. (2012–2024)
Year-by-year debt coverage analysis for Zevra Therapeutics Inc.. Check how high is Zevra Therapeutics Inc.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.50x | $-69.67 Million | $138.46 Million | ▼ -65.7% |
| 2023 | -0.30x | $-33.53 Million | $110.46 Million | ▲ +34.8% |
| 2022 | -0.47x | $-18.72 Million | $40.22 Million | ▼ -126.0% |
| 2021 | 1.79x | $10.44 Million | $5.82 Million | ▲ +7276.5% |
| 2020 | -0.02x | $-1.94 Million | $77.62 Million | ▲ +91.1% |
| 2019 | -0.28x | $-23.74 Million | $84.96 Million | ▲ +51.9% |
| 2018 | -0.58x | $-54.20 Million | $93.31 Million | ▼ -93.0% |
| 2017 | -0.30x | $-33.10 Million | $109.97 Million | ▼ -4.7% |
| 2016 | -0.29x | $-29.77 Million | $103.58 Million | ▲ +6.6% |
| 2015 | -0.31x | $-20.27 Million | $65.84 Million | ▲ +20.3% |
| 2014 | -0.39x | $-14.67 Million | $38.02 Million | ▼ -138.2% |
| 2013 | -0.16x | $-4.33 Million | $26.70 Million | ▲ +87.0% |
| 2012 | -1.25x | $-4.43 Million | $3.56 Million | — |